Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's GRAMM-RUDMAN-HOLLINGS BUDGET CUTS COULD TOTAL $ 71 MIL

Executive Summary

FDA's GRAMM-RUDMAN-HOLLINGS BUDGET CUTS COULD TOTAL $ 71 MIL. if all cost-saving and revenue-increasing provisions under the current budget agreement between Congress and the Bush Administration are not implemented, the Congressional Budget Office predicts. CBO's projections unit, within its Budget Analysis Division, estimates that nearly $ 70 mil. in FDA program outlays and a total of more than $ 71 mil. -- accounting for costs of buildings, facilities and other services -- would be sequestered under the deficit-reduction act. Under current budget legislation, the fiscal 1990 deficit will exceed the $ 100 bil. sequestration trigger by $ 16.2 bil., according to Office of Management and Budget figures. Gramm-Rudman-Hollings requires sequestration (across-the-board budget cuts) if the deficit exceeds the target by $ 10 bil. or more. OMB estimates that a total cut of $ 23 mil. in FDA funds would be required in the absence of cost-saving and revenue-enhancing provisions in the budget agreement. The Bush Administration's projections were included in the "Initial OMB Sequester Report" for 1990. One provision of the budget agreement involves the Medicare catastrophic care program. In the first year of the program, premium-based revenues are expected to exceed outlays. Ironically, elimination of the expensive drug benefit, in an effort to reduce enrollees' premiums, would increase the overall deficit. This anomaly muddles the review of the Medicare program by the House Ways & Means and Senate Finance Committees ("The Pink Sheet" Aug. 21, p. 6).

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS016135

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel